Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma

HIV Medicine

Volumn 13, Issue 8, 2012, Pages 479-487

  Leruez Ville, M ^a   Seng, R ^b   Morand, P ^c   Boufassa, F ^b   Boue, F ^d   Deveau, C ^b   Rouzioux, C ^a   Goujard, C ^e   Seigneurin, J M ^c   Meyer, L ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

^d HÔPITAL ANTOINE BÉCLÈRE   (France)

^e BICÊTRE HOSPITAL   (France)

Author keywords

AIDS related lymphoma; B systemic lymphoma; Barr virus; Epstein; HIV; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; B CELL LYMPHOMA; BRAIN LYMPHOMA; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; INFECTION RISK; MALE; MONOTHERAPY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, B-CELL; MALE; ODDS RATIO; VIRAL LOAD;

EID: 84864325482     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.00998.x     Document Type: Article

References (32)

1. Goedert JJ, Cote TR, Virgo P etal. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351: 1833-1839.
2. Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol 2000; 27: 442-453.
3. Besson C, Goubar A, Gabarre J etal. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98: 2339-2344.
4. Stebbing J, Gazzard B, Mandalia S etal. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 2177-2183.
5. Lewden C, May T, Rosenthal E etal. Changes in causes of death among adults infected by HIV between 2000 and 2005: the 'Mortalite 2000 and 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48: 590-598.
6. Bruyand M, Thiebaut R, Lawson-Ayayi S etal. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 2009; 49: 1109-1116.
7. Bower M, Fisher M, Hill T etal. CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica 2009; 94: 875-880.
8. Carbone A. AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Hum Pathol 2002; 33: 392-404.
9. van Esser JW, Niesters HG, van der Holt B etal. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-4369.
10. Bonnet F, Jouvencel AC, Parrens M etal. A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma. J Clin Virol 2006; 36: 258-263.
11. Styczynski J, Reusser P, Einsele H etal. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43: 757-770.
12. Wagner HJ, Wessel M, Jabs W etal. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001; 72: 1012-1019.
13. Wagner HJ, Cheng YC, Huls MH etal. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979-3981.
14. Ling PD, Vilchez RA, Keitel WA etal. Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2003; 37: 1244-1249.
15. Amiel C, Legoff J, Lescure FX etal. Epstein-Barr virus load in whole blood correlates with HIV surrogate markers and lymphoma: a French national cross-sectional study. J Acquir Immune Defic Syndr 2009; 50: 427-429.
16. Van Baarle D, Wolthers KC, Hovenkamp E etal. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis 2002; 186: 405-409.
17. Seng R, Rolland M, Beck-Wirth G etal. Trends in unsafe sex and influence of viral load among patients followed since primary HIV infection, 2000-2009. AIDS 2011; 25: 977-988.
18. Madec Y, Boufassa F, Avettand-Fenoel V etal. Early control of HIV-1 infection in long-term nonprogressors followed since diagnosis in the ANRS SEROCO/HEMOCO cohort. J Acquir Immune Defic Syndr 2009; 50: 19-26.
19. Fan H, Kim SC, Chima CO etal. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol 2005; 75: 59-69.
20. Corcoran C, Rebe K, van der Plas H, Myer L, Hardie DR. The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons. J Clin Virol 2008; 42: 433-436.
21. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010; 23: 350-366.
22. Gartner B, Preiksaitis JK. EBV viral load detection in clinical virology. J Clin Virol 2010; 48: 82-90.
23. Stevens SJ, Pronk I, Middeldorp JM. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 2001; 39: 1211-1216.
24. Broccolo F, Bossolasco S, Careddu AM, Tambussi G, Lazzarin A, Cinque P. Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance. Clin Diagn Lab Immunol 2002; 9: 1222-1228.
25. Hakim H, Gibson C, Pan J etal. Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood. J Clin Microbiol 2007; 45: 2151-2155.
26. Tsai DE, Douglas L, Andreadis C etal. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 2008; 8: 1016-1024.
27. Zoufaly A, Stellbrink HJ, Heiden MA etal. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis 2009; 200: 79-87.
28. Gasser O, Bihl FK, Wolbers M etal. HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med 2007; 4: e96.
29. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10: 1152-1159.
30. Bohlius J, Schmidlin K, Boue F etal. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood 2010; 117: 6100-6108.
31. Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR. Immune reconstitution and risk of kaposi sarcoma and nonhodgkin lymphoma in HIV-infected adults. AIDS 2011; 25: 1395-1403.
32. Stevens SJ, Smits PH, Verkuijlen SA etal. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription. AIDS 2007; 21: 2141-2149.